Beyond Meat, Inc. has released its financial results for the third quarter of 2026, highlighting a decline in revenues and a substantial loss from operations. The results, announced on November 4, 2026, indicate ongoing challenges for the plant-based food company as it navigates a competitive market.
Beyond Meat, Inc. operates in the food and kindred products sector and is listed on the Nasdaq under the ticker BYND. The company, incorporated in Delaware, has been a pioneer in the plant-based protein market, aiming to provide alternatives to traditional meat products. Recent filings show a series of reports leading up to this announcement, including quarterly and annual updates.
The latest filing reveals that for the third quarter ended September 26, 2026, Beyond Meat reported total net revenues of $64.5 million, reflecting an 8.1% decrease year-over-year. The gross profit for the quarter was $12.4 million, with a gross margin of 19.3%. This marks a significant improvement from the previous year's gross profit of $5.2 million, but the company still reported a loss from operations of $93.0 million.
The filing states, “Total net revenues were $64.5 million, a decrease of 8.1% year-over-year.” It also mentions that the gross profit was $12.4 million, with a gross margin of 19.3%, compared to the previous year's gross margin of 7.4%.
This financial update is likely to impact various stakeholders, including investors, employees, and suppliers. The decline in revenues and ongoing losses may raise concerns about the company's growth trajectory and financial health. Moreover, as Beyond Meat continues to face competition from other players in the food and kindred products sector, the implications for the broader industry could be significant.
Looking ahead, the filing does not specify what actions Beyond Meat will take in response to these results. However, the company is expected to continue focusing on innovation and market expansion to regain momentum in a challenging environment.
Read Next
Liberty Latin America reports Q3 2026 results amid challenges
Mineralys Therapeutics Reports Q3 2026 Financial Results
ADMA Biologics reports quarterly results, highlights growth
ProtoKinetix Reports Q1 2026 Results Amid Industry Challenges
National Healthcare Properties reports Q3 2026 results
Encore Capital Group Reports Q3 2026 Financial Results




